Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.
Keywords: Antigen cross-presentation; DAMPs; TLR signaling; clinical trial; immune checkpoint blockers; plasmacytoid dendritic cells; tumor-infiltrating lymphocytes.
© 2019 Taylor & Francis Group, LLC.
Trial Watch: Dendritic Cell-Based Anticancer ImmunotherapyAD Garg et al. Oncoimmunology 6 (7), e1328341. PMID 28811970. - ReviewDendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patie …
Trial Watch: Dendritic Cell-Based Anticancer TherapyN Bloy et al. Oncoimmunology 3 (11), e963424. PMID 25941593. - ReviewThe use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throu …
Eliciting Cytotoxic T Lymphocytes Against Human Laryngeal Cancer-Derived Antigens: Evaluation of Dendritic Cells Pulsed With a Heat-Treated Tumor Lysate and Other Antigen-Loading Strategies for Dendritic-Cell-Based VaccinationFQ Wei et al. J Exp Clin Cancer Res 35, 18. PMID 26795730.These data suggest that DC-TSL is a more potent inducer of antitumor immunity against laryngeal cancer than other antigen-loading strategies using whole tumor cell materi …
Clinically Feasible Approaches to Potentiating Cancer Cell-Based ImmunotherapiesVI Seledtsov et al. Hum Vaccin Immunother 11 (4), 851-69. PMID 25933181. - ReviewThe immune system exerts both tumor-destructive and tumor-protective functions. Mature dendritic cells (DCs), classically activated macrophages (M1), granulocytes, B lymp …
Dendritic Cell-Tumor Cell Hybrids Enhance the Induction of Cytotoxic T Lymphocytes Against Murine Colon Cancer: A Comparative Analysis of Antigen Loading Methods for the Vaccination of Immunotherapeutic Dendritic CellsT Yasuda et al. Oncol Rep 16 (6), 1317-24. PMID 17089056.Dendritic cells (DCs) have been used successfully for inducing effective anti-tumor immune responses in advanced cancer patients undergoing tumor-specific immunotherapy. …
Cited by 1 PubMed Central articles
Trial Watch: Chemotherapy-Induced Immunogenic Cell Death in Immuno-OncologyI Vanmeerbeek et al. Oncoimmunology 9 (1), 1703449. PMID 32002302. - ReviewThe term 'immunogenic cell death' (ICD) denotes an immunologically unique type of regulated cell death that enables, rather than suppresses, T cell-driven immune response …